SynthesisPloS one2014
Quantification of heterogeneity as a biomarker in tumor imaging: a systematic review.
Synthesis in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 84 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
84 citing papers in PubMed, 3 syntheses or guidelines pooled it, 160 citations in OpenAlex.
- Reproducibility analysis of multi-institutional paired expert annotations and radiomic features of the Ivy Glioblastoma Atlas Project (Ivy GAP) dataset.Medical physics · 2020Pooled it
- Quantitative magnetic resonance imaging and radiogenomic biomarkers for glioma characterisation: a systematic review.The British journal of radiology · 2018Pooled it
- Quantification of heterogeneity as a biomarker in tumor imaging: a systematic review.PloS one · 2014Pooled it
- Trial
- B-Mode Ultrasound Radiomics for Differentiating Benign and Malignant Small Hyperechoic Renal Masses: An Exploratory Single-Center Experience.Journal of imaging · 2026Article
- Multimodal MRI-based nomogram integrating clinical-radiological, radiomic, and habitat features to discriminate solitary fibrous tumors from atypical meningiomas.Scientific reports · 2026Article
- Radiomics in laryngeal squamous cell carcinoma: state of the art.Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale · 2026Review
- Simultaneous detection of lymphocytes and tumor cellsNanoscale horizons · 2026Article
- High-Fructose Corn Syrup on Inflammation and Cancer.World journal of oncology · 2025Review
- Cortical thickness deviations as biomarker for subtyping and prognosis in pediatric brainstem tumors.Scientific reports · 2025Article
- Prospective longitudinal analysis of physiologic MRI-based tumor habitat predicts short-term patient outcomes in IDH-wildtype glioblastoma.Neuro-oncology · 2025Article
- A Machine Learning Model Based on Radiomic Features as a Tool to Identify Active Giant Cell Arteritis on [Diagnostics (Basel, Switzerland) · 2025Article
- Article
- Difference in Laterality of the Dorsal Striatum in Schizoaffective Disorder.Actas espanolas de psiquiatria · 2024Article
- Enhanced Diagnostic Precision: Assessing Tumor Differentiation in Head and Neck Squamous Cell Carcinoma Using Multi-Slice Spiral CT Texture Analysis.Journal of clinical medicine · 2024Article
- Article
- radioGWAS links radiome to genome to discover driver genes with somatic mutations for heterogeneous tumor image phenotype in pancreatic cancer.Scientific reports · 2024Article
- Precision Phenotypic Profiling and Capture of Circulating Tumor Cells via a Vertical Laminar Flow-Stacked Microfluidic Chip.Micromachines · 2024Article
- Ultrafast MRI and T1 and T2 Radiomics for Predicting Invasive Components in Ductal Carcinoma in Situ Diagnosed With Percutaneous Needle Biopsy.Korean journal of radiology · 2023Article
- Machine learning for predicting accuracy of lung and liver tumor motion tracking using radiomic features.Quantitative imaging in medicine and surgery · 2023Article
24 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMany techniques are proposed for the quantification of tumor heterogeneity as an imaging biomarker for differentiation between tumor types, tumor grading, response monitoring and outcome prediction. However, in clinical practice these methods are barely used. This study evaluates the reported performance of the described methods and identifies barriers to their implementation in clinical practice. METHODOLOGY: The Ovid, Embase, and Cochrane Central databases were searched up to 20 September 2013. Heterogeneity analysis methods were classified into four categories, i.e., non-spatial methods (NSM), spatial grey level methods (SGLM), fractal analysis (FA) methods, and filters and transforms (F&T). The performance of the different methods was compared. PRINCIPAL
findingsOf the 7351 potentially relevant publications, 209 were included. Of these studies, 58% reported the use of NSM, 49% SGLM, 10% FA, and 28% F&T. Differentiation between tumor types, tumor grading and/or outcome prediction was the goal in 87% of the studies. Overall, the reported area under the curve (AUC) ranged from 0.5 to 1 (median 0.87). No relation was found between the performance and the quantification methods used, or between the performance and the imaging modality. A negative correlation was found between the tumor-feature ratio and the AUC, which is presumably caused by overfitting in small datasets. Cross-validation was reported in 63% of the classification studies. Retrospective analyses were conducted in 57% of the studies without a clear description.
conclusionsIn a research setting, heterogeneity quantification methods can differentiate between tumor types, grade tumors, and predict outcome and monitor treatment effects. To translate these methods to clinical practice, more prospective studies are required that use external datasets for validation: these datasets should be made available to the community to facilitate the development of new and improved methods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.